Making blood on demand: How far have we come? – Science Codex

The reconstitution of the blood system in humans holds great therapeutic potential to treat many disorders, like blood cancers, sickle-cell anemia and others. Successful reconstitution requires the transplantation and engraftment of hematopoietic (or blood) stem cells (HSCs), which after reaching their niche, start producing all types of blood cells, including platelets, white and red blood cells.

In current clinical practice, this is carried out by infusing HSCs obtained from a matched donor who is immunologically compatible with the patient in need (allogeneic transplantation), or by the expansion of the patient's own HSCs in the lab, and then re-infusing them back into the patient (ex-vivo, autologous transplantation). However, the utility of both routes is currently limited by a number of factors. First, in the case of allogeneic transplantation, the scarcity of matched donors significantly increases the waiting time, which could be detrimental to the patient. Second, the ex vivo expansion of HSCs, whether allogeneic or autologous, has been a challenging task, due to the limited proliferative potential these cells exhibit in culture. These limitations have raised the need for other sources of HSCs that would alleviate the need for matched donors and yield functional HSCs in large quantities.

In 2007, Professor Shinya Yamanaka and colleagues demonstrated that somatic cells, like skin fibroblasts, could be reprogrammed back to a cellular state that resembled human embryonic stem cells (hESCs), which are a group of cells found in the blastocyst-stage human embryo and contribute solely to the development of the human fetus during pregnancy. The reprogrammed cells were termed, Induced Pluripotent Stem Cells (iPSCs). In addition to their developmental potential, human ESCs and iPS cells display unlimited proliferative potential in culture, which makes them an ideal source of cells for regenerative medicine in general and for hematopoietic differentiation to obtain possibly unlimited quantities of HSCs. Therefore, there has been a growing interest to harness the potential of these cells for treating blood disorders.

However, advancement in deriving functional HSCs from human pluripotent stem cells has been slow. This has been attributed to incomplete understanding of the molecular mechanisms underlying normal hematopoiesis. In this review, the authors discuss the latest efforts to generate HSCs capable of long-term engraftment and reconstitution of the blood system from human pluripotent stem cells. Stem cell research has witnessed milestone achievements in this area in the last couple of years, the significance of which are discussed and analyzed in detail.

The authors additionally discuss two highly important families of transcription factors in the context of hematopoiesis and hematopoietic differentiation, the Homeobox (HOX) and GATA proteins. These are thought of as master regulators, in the sense of having numerous transcriptional targets, which upon activation, could elicit significant changes in cell identity. The authors hypothesize that precise temporal control of the levels of certain members of these families during hematopoietic differentiation could yield functional HSCs capable of long-term engraftment.

The authors conclude the review with a summary of future perspectives, in which they discuss how newly developed techniques, like the deactivated-Cas9 (dCas9) gene-expression control system, can be utilized during the course of hematopoietic differentiation of pluripotent stem cells for precise temporal control of the aforementioned master regulators to achieve functional HSCs.

Read this article:
Making blood on demand: How far have we come? - Science Codex

Stem Cells Market Key Opportunities and Forecast up to 2025 – AnalyticSP

In theglobalstem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market are STEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

Request PDF Sample of Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Enquiry for Discount on Stem Cells Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

See the original post here:
Stem Cells Market Key Opportunities and Forecast up to 2025 - AnalyticSP

How reindeer might help deliver the gift of scar-free healing to humans – The Globe and Mail

Almost 30 reindeer live on pastureland on the outskirts of Calgary where Jeff Biernaskie is among the researchers trying to determine if their unique healing abilities can be applied to human skin.

Todd Korol/The Globe and Mail

Kyle Hynes is 27. He likes kayaking, fishing and hiking with his dogs around the Rocky Mountains. He is a project manager at a helicopter company and talks with his hands when he gets excited.

He believes reindeer may hold the secret to making his life even better.

When Mr. Hynes was 5, he survived a house fire that left him with scars over 80 per cent of his body and forced him to endure years of surgeries.

Story continues below advertisement

I do love my scars now, he said. But if I could get rid of my scars, I would be the happiest guy alive.

Mammals scar when serious skin wounds heal. Reindeer, however, are among the few exceptions to the rule, with the velvet on their antlers, specifically, healing flawlessly. Scientists at the University of Calgary believe human skin has the potential to heal with the same reindeer magic.

Almost 30 of the creatures live on pastureland on the outskirts of Calgary. Jeff Biernaskie is among the researchers experimenting on the animals. He is a cell biologist and neurobiologist by training focused on tissue regeneration. His team is trying to figure out how to make human skin respond to injury the way reindeer velvet does. The research has the potential restore both the appearance and function of skin for people such as Mr. Hynes.

Jeff Biernaskie is a cell biologist researching how reindeer velvet heals.

Todd Korol/The Globe and Mail

Reindeer sport velvet on their antlers for three to four months a year. The oily brown fuzz protects the antlers as they grow back each year. Reindeer both male and female depend on antlers for scrounging up food under the snow and for protection from predators. Males also show off their racks in mating season.

Dr. Biernaskie originally wanted to isolate the cells that might be responsible for antler growth, long thought to be stem cells that reside in two bony structures, called pedicles, on either side of the skull. Using anesthetic, his team removed small pieces of skin in order to access the pedicle and noticed that the wounds healed without scarring. Then they made more purposeful wounds and found the velvet regenerated seamlessly. By way of comparison, the scientists inflicted identical wounds elsewhere on the reindeers bodies and noted that the animals scarred at those sample sites.

When mammals are wounded, skin cells around the injury and the immune system rush to seal the site as quickly as possible to prevent infection. The natural response to injury, Dr. Biernaskie believes, is regenerative, but those signals are overwhelmed by scar-forming ones in the race to close the wound.

This, however, does not apply to embryonic cells, which are strictly regenerative. Fetal humans, Dr. Biernaskie says, heal perfectly. He says the cells that make up reindeer velvet exhibit genetic properties similar to those in embryonic cells. So if his team can activate regenerative genes and suppress those that form scars, humans may be able to regrow damaged tissue without flaws.

Story continues below advertisement

It is almost like a circuit breaker," Dr. Biernaskie said. You have some that need to be turned on and others that need to be turned off.

Drugs, administered topically or intravenously, may be able to flip the switch, and Dr. Biernaskies lab is experimenting on mice.

His team has been working on the reindeer project for about five years and expects to reveal its findings next year. (The animals are known as caribou in North America and reindeer in Europe. The Calgary herd comes from European stock, so Dr. Biernaskie is sticking with reindeer in casual conversation. Also, its Christmas.)

Scars can be psychologically and physically disabling. Scars on joints, for example, limit mobility.

That becomes a massive burden on our economy, on our health-care system, but also on their quality of life, Dr. Biernaskie said.

Five years ago, the Calgary Firefighters Burn Treatment Society donated $1-million its largest single charitable contribution to support Dr. Biernaskies work. It put up another $1-million this year after his teams progress exceeded expectations.

Story continues below advertisement

Mr. Hynes recognizes that science moves slowly but remains optimistic that he may benefit from Calgarys reindeer.

I live life to the fullest, but when I see this research come out, I get really excited to know that [there is] a possibility it could work for me, he said. [And] for other children who do get burns, theres something there that might cure them.

We have a weekly Western Canada newsletter written by our B.C. and Alberta bureau chiefs, providing a comprehensive package of the news you need to know about the region and its place in the issues facing Canada. Sign up today.

Read the rest here:
How reindeer might help deliver the gift of scar-free healing to humans - The Globe and Mail

Chinese Researchers Created the First PigMonkey Chimera – Science Times

(Photo : Pixabay)

Chinese researchers developed two piglets that were a hybrid of a pig and a monkey.

Monkey stem cells were injected into fertilized pig embryos to generate the pigmonkey chimera. These were subsequently implanted intosurrogate sows.Chimeras were a result of these piglets, which means that they contained DNA from a pig and a monkey.

"This is the first report of full-term pig-monkey chimeras," co-author Tang Hai, a researcher at the State Key Laboratory of Stem Cell and Reproductive Biology in Beijing, told New Scientist.

The main goal of Hai and his co-researchers were for the growth of human organs in animals for transplant procedures. The team has received ethical qualms related to the development ofhumananimal chimeras.

Mechanism on the Growth of the PigMonkey Chimera

The cells of cynomolgus monkeys (Macaca fascicularis) were grown in lab dishes. TheDNA cellswere provided steps to build a fluorescent protein that aimed to change the DNA. A bright green glow was a result of this protein. Embryonic stem cells resulted from these luminescent cells that were injected into prepared pig embryos. Monkey cells were tracked by the researchers through these luminescent spots.

A total of 4,000 embryos were recipients of the monkey cell injection and were subsequently implanted in surrogate pigs. Ten piglets were born out of these sows but only two grew both pig and monkey cells. The team used the luminescent protein to scan for the monkey cells through different organs. The hybrid chimeras were comprised of 99% pig as there is one in 1,000 monkey cells in each organ.

The low ratio of monkey to pig cells still is greater compared with the 2017 humanpig chimera that was grown by scientists. The said chimera was only permitted to develop for a month since there is a possibility that the brain might grow human cells and provide the animal with a human-like consciousness.

Ethical Issues

The pressure from the scientific ethics committee did not stop the team from creating humanmonkey chimeras early this 2019. The results of the said experiment were not published, but the researchers only allowed the humanprimate chimera a few weeks to develop.

Despite the success achieved by Hai and his co-authors, stem cell biologist Paul Knoepler of the University of California, Davis was not impressed with the results as it is discouraging because of the low ration of monkey-to-pig cells.

"The exact reason for the piglets' death remains "unclear," Hai told New Scientist, but he said that he suspects the deaths are linked to the in vitro fertilization (IVF) procedure rather than the injection of monkeyDNA. Other scientists have also found that IVF doesn't consistently work in pigs, according to a 2019 report in the journalTheriogenology," as reported byLive Science.

Hai and his team aim to increase the ratio of monkey cells to pig cells in future chimeras. The researchers aim to be able to grow human organs in animals for organ transplant procedures and to help in the field of human health.

Go here to read the rest:
Chinese Researchers Created the First PigMonkey Chimera - Science Times

How Will Animals Get Benefitted by Stem Cell Therapy? – Medical Tech Outlook

ESPCs derived from pig provide important implications for developmental biology, organ transplantation, regenerative medicine, disease modeling, and screening for drugs.

FREMONT, CA: Stem cell therapy, usually applied to humans, is now extended to animals too. It is a regenerative treatment applied to cats, dogs, pigs, and other animals. It includes removing cells from bone marrow, blood or fat, umbilical cords, and the cell can grow into any kind of cell and can repair damaged tissues. The regenerative therapy has been successful in animals. It can be used mainly for the treatment of spinal cord and bone injuries along with the problems with tendons, ligaments, and joints. One of the breakthroughs is the embryonic stem cell lines obtained from the pig.

Scientists have derived Expanded Potential Stem Cells (EPSCs) from pig embryos for the first time. They offer the groundbreaking potential to study embryonic development and produce translational research in genomics and regenerative medicine. Embryonic stem cells (ESC) are derived from the inner cells of early embryos called blastocysts. They are pluripotent cells as they can develop into various cell types of the body in the culture dish. The newly derived porcine EPSCs isolated from pig embryos are the first well-characterized cell lines worldwide. Their pluripotent ability provides important implications for developmental biology, organ transplantation, regenerative medicine, disease modeling, and screening for drugs.

The stem cells can renew themselves, showing that they can be kept in culture indefinitely while showing the typical morphology and gene expression patterns of embryonic stem cells. Because somatic cells have a limited lifespan, they cannot be used for such applications, and therefore the new stem cells are better suited for the lengthy selection process. These porcine stem cell lines can easily be edited with new genome editing techniques like CRISPR/Cas, and are currently the simplest, most versatile and precise method of genetic manipulation.

The EPSCs have a greater capacity to develop into numerous cell types of the organism as well as into extraembryonic tissue, the trophoblasts, rending them very unique and, thus, their name. This capacity is valuable for the future promising organoid technology where organ-like small cell aggregations are grown in 3D aggregates and used for research into early embryo development, various disease models, and testing of new drugs in Petri dishes. Also, they offer a unique possibility to investigate functions or diseases of the placenta in vitro.

See the article here:
How Will Animals Get Benefitted by Stem Cell Therapy? - Medical Tech Outlook

14 Advantages and Disadvantages of Embryonic Stem Cell …

Embryonic stem cells are derived from embryos that develop from eggs that were created through the in vitro fertilization process. These eggs are then donated for research purposes with the informed consent of their donors. Researchers do not derive embryonic stem cells from eggs that are fertilized in a womans body.

Women do not have abortions to harvest their embryonic stem cells, nor do any providers sell fetal tissue for these cell lines to develop.

Human embryonic stem cells come from a transference of cells from a preimplantation-stage embryo in a laboratory culture dish. It is mixed with culture medium, allowing the cells to divide, and then spread over the surface of this dish. These cells can then develop into all three derivatives of the primary germ layers, making it possible for them to eventually turn into one of the over 200 different cell types that are found in the human body.

It is not possible to save the embryo when these cells are harvested from it, which ends the potential future viability of human life. That is where a majority of the embryonic stem cell research pros and cons focus on when discussing this subject. How you personally define human life will usually dictate which side of the debate you support.

1. The embryonic stem cells are harvested 5-7 days after conception.Adult stem cells do not provide the same benefits as embryonic ones from a therapeutic standpoint. They fall short in their viability to treat genetic diseases. Thats because the same disease found in the adult body can be present in their stem cells. When the harvesting takes place, it occurs during the first week after conception. At this stage, the embryo has not yet developed to a stage where a personal identity can be assigned to it, nor can it live outside of a specialized environment. It is essentially a mass of cells.

2. Researchers use the embryonic stem cells from discarded embryos.The IVF process which creates embryos for transplantation in the first place are often discarded without a second though. Reporting by The Telegraph in 2012 found that over 1.7 million human embryos were discarded during or after the conception process. Between 1991-2012, there were 3.5 million human embryos created, but only roughly 235,000 successful implantation procedures. About 840, 000 were put into cold storage, while just 2,000 were stored for donation.

Approximately 6,000 embryos during this two-decade period were set aside for medical research. Compared to the 1.4 million that were implanted as a way to start a pregnancy, where 1 in 6 failed, the issue of morality is more complex than the black-and-white world that some people create.

3. Embryonic stem cells can be harvested ethically from almost any perspective.New technologies make it possible for doctors to harvest remaining embryonic stem cells from the umbilical cord after a child is born. Even if parents decide to store cord blood instead of make a donation, the product can still contain a line of embryonic stem cells that could be useful for research purposes. Since the umbilical cord doesnt stay attached to the child, nor does the cord blood get reabsorbed into the mother or the baby, the only way to unethically take this resource is to do it without asking.

4. Pain is not felt during the embryonic stem cell procedure.When researchers destroy an embryo as they harvest the line of stem cells that develops, there is no pain experienced by this cell group. Researchers believe that a fetus doesnt have the concept of pain developed until around the 20th week of gestation. Most of the embryos that are used for this process have been frozen anyway, kept in storage because there is no intention to use the cells to hopefully create a pregnancy one day anyway.

Fetal tissues wouldnt supply the embryonic stem cells anyway because at that stage of development, they have already turned into what they are going to be. That makes it virtually impossible to study their qualities at the level where they would be medically beneficial.

5. No embryonic stem cells are taken without consent.IVF doctors dont take fertilized eggs away from women or couples with an evil laugh, thinking about all the dastardly ways they can manipulate embryonic stem cells for personal gain. People dont steal frozen embryos, encourage abortions, or harvest the tissues from a growing fetus to serve a medical or political agenda. Every embryonic stem cell line comes from the consent of its donor. No research on those cells will take place unless there is explicit consent offered by those involved.

6. We do not know the full potential of this new field of medical science.We are still in the early stages of research to determine the full potential value of embryonic stem cells as a treatment option for some individuals. As the University of Michigan notes, it may lead to more effective treatments for serious human ailments. The future discoveries in this field could alleviate the suffering for millions of people around the world. Spinal cord injuries, Parkinsons disease, Alzheimers disease, and juvenile diabetes are just a few of the conditions which could be improved if medical studies are given time and funding to reach a conclusion.

7. Treatments using embryonic stem cells have already produced results.Early embryonic stem cell treatments through the use of cord blood therapies have already produce positive outcomes for roughly 10,000 people. These treatments offer new ways to find a cure for 70+ different diseases with this option. Kids that have an immunodeficiency disorder and receive this form of treatment see a treatment success rate of 90% today and that figure continues to grow.

1. It destroys the future potential of human life.Whether you feel that life begins at conception, at some stage in the womb, or after birth, everyone can agree on the idea that an embryo represent the future potential of life. We can get lost in the semantics of how life begins to support how we feel, but the bottom line here is that the termination of an embryo stops the future potential for that group of cells. Using it for research purposes, even with the consent of the mother or couple involved, means youre trading future human potentiality for current potentiality. Is that really a justifiable action?

2. The number of successful treatment outcomes is relatively minor.There are significant barriers in place when looking at the potential of an embryonic stem cell treatment. There are unstable gene expressions which occur when this method is used, along with the formation of tumors, and some people even see a failure in the cells ability to activate to a specific purpose. Until these challenges are addressed in clinical settings, the full potential of this treatment can never be realized. Does it make sense to continue harvesting cells from embryos if the failure rate remains high?

3. People can still reject embryonic stem cell treatments.The human body naturally rejects the items that are not part of its regular genetic makeup through its immune system response. That is why the people who go through an organ transplant procedure receive anti-rejection medication that slows or stops this response. Even if the embryonic stems cells go through their regular activation method, there is still the potential of rejection present.

Even if an embryonic clone of an individual could be created to product exact cells which mimic the bodys genetic makeup, there would still be a risk of rejection because of the genetic duplication process.

4. It can be argued that embryos do meet the definition of life from a scientific view.There are currently three specific guidelines in the framework of the definition of life as we think of it when encountered on our planet or perhaps elsewhere in our solar system or galaxy one day.

There must be a capacity for growth that produces functional activity. It must offer some type of reproduction capability during one stage of its existence. There must be a change which occurs over the lifetime of the cells in question that happens before death.

5. People fund research activities with their taxes.Federal law in the United States prohibits taxpayer funding to be used for abortion services unless specific exceptions apply. What many people do not realize is that over $500 million in research funding has been given to this medical field since 1996 because even though portions of this field were outlawed, all existing stem cell lines currently being worked on at the time were grandfathered into the legislative process.

The Supreme Court affirmed the federal stem cell research could continue in 2013 despite a long-running appeal that such an action is a violation of the Dickey-Wicker Act that prohibits the destruction of an embryo.

6. It is a time-consuming process to create viable embryonic stem cells.For the stem cells to become a viable research tool, they must undergo several months of development in strict laboratory conditions before they are valuable in any way. Then there is the cost involved with the process as well. The 2017 estimated federal funding for all categories of stem cell research was $1.58 billion. Embryonic stem cell research received $347 million, while umbilical cord blood or placenta-based stem cells received $34 million.

7. Many of the stem cell lines under research are two decades old.Most of the approved embryonic stem cell research lines that are worked on in the United States were created on or before August 2001. Those lines were found to be contaminated with animal proteins, which seems to have prevented any of them from being created as a model to treat human disease. Only 16 out of the 70 lines approved by the federal government remain because a majority of them were inadequately characterized. These cells also came from an Israeli clinic, which means they do not incorporate the levels of racial and ethnic diversity that genuine research requires.

The pros and cons of embryonic stem cells look at the potential of what this new field of medical research could provide compared to the harm it may cause. There are deeper issues here that go beyond we can or we shouldnt. Since a majority of embryos are thrown away, shouldnt there be outrage over that fact from the pro-life movement? And since 1 in 6 attempted implants fails, is there not more to consider here than the intentional actions of research? By taking a look at all sides of this issue, the debate tends to become a complex set of moral judgments made on the individual level instead of a generic right or wrong answer to determine.

Continued here:
14 Advantages and Disadvantages of Embryonic Stem Cell ...

BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program – Yahoo Finance

MELVILLE, N.Y., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (BioRestorative or the Company) (BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance on its patent application for a method of generating brown fat stem cells. This is the eighth patent issued, in the United States and other countries, for the Companys brown fat technology related to BioRestoratives metabolic program (ThermoStem Program).

Once issued in Israel, the final patent will allow for a method of isolating and differentiating a non-embryonic human brown adipose-derived stem cell into functional human brown adipocytes and a method of identifying compounds that modifies metabolic activity of human brown adipocytes. The technology is applicable for potential therapeutic uses for treating a wide range of degenerative and metabolic disorders, including but not limited to diabetes, obesity, hypertension and cardiac deficiency.

We continue to drive innovative and novel technology focusing on transformative therapies for our brown fat program, said Mark Weinreb, CEO of BioRestorative Therapies. We are pleased to add to our intellectual property library this recently issued patent by the Israeli Patent Office for our metabolic program to help power disruptive ways to treat metabolic disorders.

About BioRestorative Therapies, Inc.

BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, whether the Company will be able to consummate the private placement and the satisfaction of closing conditions related to the private placement and those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.

CONTACT:Email: ir@biorestorative.com

Read more:
BioRestorative Therapies Receives Patent in Israel For Its Metabolic Program - Yahoo Finance

Exclusive: Two pigs engineered to have monkey cells born in China – New Scientist News

By Michael Le Page

Tang Hai

Pig-primate chimeras have been born live for the first time but died within a week. The two piglets, created by a team in China, looked normal although a small proportion of their cells were derived from cynomolgus monkeys.

This is the first report of full-term pig-monkey chimeras, says Tang Hai at the State Key Laboratory of Stem Cell and Reproductive Biology in Beijing.

The ultimate aim of the work is to grow human organs in animals for transplantation. But the results show there is still a long way to go to achieve this, the team says.

Advertisement

Hai and his colleagues genetically modified cynomolgus monkey cells growing in culture so they produced a fluorescent protein called GFP. This enabled the researchers to track the cells and their descendents. They then derived embryonic stem cells from the modified cells and injected them into pig embryos five days after fertilisation.

More than 4000 embryos were implanted in sows. Ten piglets were born as a result, of which two were chimeras. All died within a week. In the chimeric piglets, multiple tissues including in the heart, liver, spleen, lung and skin partly consisted of monkey cells, but the proportion was low: between one in 1000 and one in 10,000.

It is unclear why the piglets died, says Hai, but because the non-chimeric pigs died as well, the team suspects it is to do with the IVF process rather than the chimerism. IVF doesnt work nearly as well in pigs as it does in humans and some other animals.

The team is now trying to create healthy animals with a higher proportion of monkey cells, says Hai. If that is successful, the next step would be to try to create pigs in which one organ is composed almost entirely of primate cells.

Something like this has already been achieved in rodents. In 2010, Hiromitsu Nakauchi, now at Stanford University in California, created mice with rat pancreases by genetically modifying the mice so their own cells couldnt develop into a pancreas.

In 2017, Juan Carlos Izpisua Belmontes team at the Salk Institute in California created pig-human chimeras, but only around one in 100,000 cells were human and, for ethical reasons, the embryos were only allowed to develop for a month. The concern is that a chimeras brain could be partly human.

This is why Hai and his team used monkey rather than human cells. But while the proportion of monkey cells in their chimeras is higher than the proportion of human cells in Belmontes chimeras, it is still very low.

Given the extremely low chimeric efficiency and the deaths of all the animals, I actually see this as fairly discouraging, says stem cell biologist Paul Knoepfler at the University of California, Davis.

He isnt convinced that it will ever be possible to grow organs suitable for transplantation by creating animal-human chimeras. However, it makes sense to continue researching this approach along with others such as tissue engineering, he says.

According to a July report in the Spanish newspaper El Pas, Belmontes team has now created human-monkey chimeras, in work carried out in China. The results have not yet been published.

While interspecies chimerism doesnt occur naturally, the bodies of animals including people can consist of a mix of cells. Mothers have cells from their children growing in many of their organs, for instance, a phenomenon called microchimerism.

Journal reference: Protein & Cell, DOI: 10.1007/s13238-019-00676-8

More on these topics:

Go here to see the original:
Exclusive: Two pigs engineered to have monkey cells born in China - New Scientist News

Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson’s Disease – P&T…

SAN DIEGO, Dec. 12, 2019 /PRNewswire/ -- Aspen Neuroscience, Inc. today announced its launch following a $6.5 million seed round led by Domain Associates and Axon Ventures and including Alexandria Venture Investments,Arch Venture Partners,OrbiMedand Section 32 to develop the first autologous cell therapies for Parkinson's disease. Aspen's proprietary approach was developed by the company's co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Loring's lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinson's disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

Parkinson's disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. The company's research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinson's disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinson's disease.

As an autologous cell therapy for Parkinson's disease, Aspen's treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinson's disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinson's disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinson's Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the world's rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

"Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinson's disease," said Dr. Federoff. "We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist."

Aspen's lead product (ANPD001) is currently undergoing investigational new drug (IND)-enabling studies for the treatment of sporadic Parkinson's disease. Aspen is also developing a gene-edited autologous neuron therapy (ANPD002) that is in the research stage and targeted toward familial forms of Parkinson's disease beginning with the most common genetic variant in the gene encoding glucocerebrosidase (GBA). Aspen leverages proprietary machine-learning tools and artificial intelligence to ensure quality control during manufacturing and to deliver a safe and reproducible product for each cell line.

"Aspen's financial backing, combined with its experienced and proven leadership team, positions it well for future success," said Kim P. Kamdar, Ph.D., Partner at Domain Associates, one of Aspen's seed investors. "Domain prides itself on investing in companies that can translate scientific research into innovative medicines and therapies that make a difference in people's lives. We clearly see Aspen as fitting into that category, as it is the only company using a patient's own cells for replacement therapy in Parkinson's disease."

About Aspen Neuroscience

Aspen Neuroscience Inc. is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinson's disease. Aspen's therapies are based upon the scientific work of world-renowned stem cell scientist, Dr. Jeanne Loring, who has developed a novel method for autologous neuron replacement. For more information and important updates, please visithttp://www.aspenneuroscience.com.

View original content to download multimedia:http://www.prnewswire.com/news-releases/aspen-neuroscience-launches-with-6-5-million-seed-funding-to-advance-first-of-its-kind-personalized-cell-therapy-for-parkinsons-disease-300973830.html

SOURCE Aspen Neuroscience

See the article here:
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease - P&T...

Aspen Neuroscience launches with $6.5M seed funding to develop personalized and autologous cell therapy for Parkinson’s disease – TechStartups.com

Parkinsons disease is characterized by the loss of specific brain cells that make the chemical dopamine. Without dopamine, nerve cells cannot communicate with muscles and people are left with debilitating motor problems. Aspen is focusing on human pluripotent stem cells, cultured cells that can become any cell type in the human body. Many health technology startups are on the raise to cure this disease. At the forefront is Aspen Neuroscience, a healthtech startup developing first-of-its-kind personalized cell therapy for Parkinsons disease.

Aspen Neuroscience is a development stage, private biotechnology company that uses innovative genomic approaches combined with stem cell biology to deliver patient-specific, restorative cell therapies that modify the course of Parkinsons disease.

Today,Aspen Neuroscience announced its official launch with $6.5 million seed financingto develop the first autologous cell therapies for Parkinsons disease.The round was led by Domain Associates and Axon Ventures and including Alexandria Venture Investments, Arch Venture Partners, OrbiMed and others.

Aspens proprietary approach was developed by the companys co-founders, Jeanne F. Loring, Ph.D., Professor Emeritus and founding director of the Center for Regenerative Medicine at The Scripps Research Institute, and Andres Bratt-Leal, Ph.D., a former post-doctoral researcher in Dr. Lorings lab. The company was initially supported by Summit for Stem Cell, a founding partner and non-profit organization which provides a variety of services for people with Parkinsons disease. Aspen is led by industry veteran Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer.

The companys research is specific to induced pluripotent stem cells (iPSCs), which it develops by taking a skin biopsy from a person with Parkinsons disease and turning the tissue into pluripotent stem cells using genetic engineering. Aspen then differentiates the pluripotent stem cells into dopamine-releasing neurons that can be transplanted into that same person (autologous), thereby restoring the types of neurons lost in Parkinsons disease.

As an autologous cell therapy for Parkinsons disease, Aspens treatment would eliminate the need for immunosuppression because the neurons are transplanted back into the same patient from which they were generated. The use of immunosuppression is necessary with currently available cell therapies for Parkinsons disease and when transplanting cells from one patient to another (allogeneic) to prevent rejection but can pre-dispose the patient to life-threatening complications including infection and add cost to the patient and health system. Aspen is the only company in the world offering an autologous neuron replacement therapy for Parkinsons disease.

Aspen encompasses a powerful executive leadership team including Dr. Federoff who, in addition to his leadership roles at the UC Irvine Health System, was the Executive Vice President for Health Sciences and the Executive Dean of Medicine at Georgetown University. Dr. Federoff also has significant biotech industry experience including co-founding MedGenesis Therapeutix and Brain Neurotherapy Bio, as well as leading the U.S. Parkinsons Disease Gene Therapy Study Group. The company is also proud to announce the addition of several experienced and well-known members to its leadership team including Edward Wirth, M.D., Ph.D., as Chief Medical Officer.

Dr. Wirth currently serves as the Chief Medical Ofcer for Lineage Cell Therapeutics where he oversees clinical development of its two therapeutic programs for spinal cord injuries and lung cancer. He received his M.D. and Ph.D. from the University of Florida in 1994 and remained to conduct postdoctoral research including leading the University of Florida team that performed the rst human embryonic spinal cord transplant in the U.S. Dr. Wirth went on to serve as the Medical Director for Regenerative Medicine at Geron Corporation where the worlds rst clinical trial of human embryonic stem cell (hESC)-derived product occurred which demonstrated initial clinical safety.

Drs. Federoff and Wirth are joined by Dr. Loring, as Chief Scientific Officer; Jay Sial, as Chief Financial Officer; Andres Bratt-Leal, Ph.D., as Vice President of Research and Development; Thorsten Gorba, Ph.D., as Senior Director of Manufacturing and Naveen M. Krishnan, M.D., M.Phil., as Senior Director of Corporate Development.

Aspen is developing a restorative, disease modifying autologous neuron therapy for people suffering from Parkinsons disease, said Dr. Federoff. We are fortunate to have such a high-caliber scientific and medical leadership team to make our treatments a reality. Our cell replacement therapy, which originated in the laboratory of Dr. Jeanne Loring and was later supported by Summit for Stem Cell and its President, Ms. Jenifer Raub, has the potential to release dopamine and reconstruct neural networks where no disease-modifying therapies exist.

Read more from the original source:
Aspen Neuroscience launches with $6.5M seed funding to develop personalized and autologous cell therapy for Parkinson's disease - TechStartups.com